ALX ONCOLOGY HOLDINGS INC (ALXO) Stock Price, Forecast & Analysis
NASDAQ:ALXO • US00166B1052
ALXO Key Statistics, Chart & Performance
The current stock price of ALXO is 2.12 USD. In the past month the price increased by 21.84%. In the past year, price increased by 100%.
ALXO Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to ALXO. When comparing the yearly performance of all stocks, ALXO is one of the better performing stocks in the market, outperforming 94.47% of all stocks.
ALXO Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ALXO. Both the profitability and financial health of ALXO have multiple concerns.
ALXO Financial Highlights
Over the last trailing twelve months ALXO reported a non-GAAP Earnings per Share(EPS) of -1.84. The EPS increased by 29.23% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -130.57% | ||
| ROE | -241.09% | ||
| Debt/Equity | 0.15 |
ALXO Forecast & Estimates
11 analysts have analysed ALXO and the average price target is 3.4 USD. This implies a price increase of 60.38% is expected in the next year compared to the current price of 2.12.
ALXO Ownership
ALXO Latest News, Press Relases and Analysis
ALXO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.13 | 410.174B | ||
| AMGN | AMGEN INC | 17.12 | 209.016B | ||
| GILD | GILEAD SCIENCES INC | 16.82 | 184.799B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.84 | 126.056B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.02 | 82.638B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.53 | 43.982B | ||
| INSM | INSMED INC | N/A | 31.848B | ||
| NTRA | NATERA INC | N/A | 28.947B | ||
| BIIB | BIOGEN INC | 12.36 | 28.152B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.44 | 21.698B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ALXO
Company Profile
ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. The company is headquartered in South San Francisco, California and currently employs 44 full-time employees. The company went IPO on 2020-07-17. The firm's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. The company is engaged in focusing on combining evorpacept with anti-cancer antibodies, antibody drug conjugate (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. Evorpacept is being evaluated across multiple ongoing clinical trials in a range of cancer indications. Its second product candidate is ALX2004, an epidermal growth factor receptor (EGFR)-targeted ADC. ALX2004 comprises an affinity-tuned EGFR antibody backbone engineered for optimal activity as an ADC, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability.
Company Info
ALX ONCOLOGY HOLDINGS INC
323 Allerton Avenue
South San Francisco CALIFORNIA 94010 US
CEO: Jaume Pons
Employees: 44
Phone: 16504667125
ALX ONCOLOGY HOLDINGS INC / ALXO FAQ
What does ALXO do?
ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. The company is headquartered in South San Francisco, California and currently employs 44 full-time employees. The company went IPO on 2020-07-17. The firm's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. The company is engaged in focusing on combining evorpacept with anti-cancer antibodies, antibody drug conjugate (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. Evorpacept is being evaluated across multiple ongoing clinical trials in a range of cancer indications. Its second product candidate is ALX2004, an epidermal growth factor receptor (EGFR)-targeted ADC. ALX2004 comprises an affinity-tuned EGFR antibody backbone engineered for optimal activity as an ADC, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability.
What is the current price of ALXO stock?
The current stock price of ALXO is 2.12 USD. The price increased by 0.47% in the last trading session.
Does ALX ONCOLOGY HOLDINGS INC pay dividends?
ALXO does not pay a dividend.
What is the ChartMill rating of ALX ONCOLOGY HOLDINGS INC stock?
ALXO has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Is ALX ONCOLOGY HOLDINGS INC (ALXO) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ALXO.
Can you provide the market cap for ALX ONCOLOGY HOLDINGS INC?
ALX ONCOLOGY HOLDINGS INC (ALXO) has a market capitalization of 114.95M USD. This makes ALXO a Micro Cap stock.